Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
G2019S mutation
LRRK2 gene
Parkinson's disease
colon cancer
leukemia
pooled analysis
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
02
05
2019
revised:
20
06
2019
accepted:
08
07
2019
pubmed:
28
7
2019
medline:
27
6
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls.
METHODS
Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients.
RESULTS
Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients.
CONCLUSIONS
The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 31348549
doi: 10.1002/mds.27807
pmc: PMC6754269
mid: NIHMS1044187
doi:
Substances chimiques
LRRK2 protein, human
EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1392-1398Subventions
Organisme : NINDS NIH HHS
ID : K02 NS073836
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS099441
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS094148
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100600
Pays : United States
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Brain Behav. 2017 Dec 07;8(1):e00858
pubmed: 29568677
Mov Disord. 2010 Nov 15;25(15):2536-41
pubmed: 20818610
JAMA Neurol. 2015 Jan;72(1):58-65
pubmed: 25401981
Parkinsonism Relat Disord. 2010 Mar;16(3):186-90
pubmed: 19945903
Cancer Epidemiol. 2017 Oct;50(Pt A):16-21
pubmed: 28763723
Lancet Neurol. 2008 Jul;7(7):583-90
pubmed: 18539534
J Neurol. 2013 Aug;260(8):2177-8
pubmed: 23824357
Neurology. 2009 Oct 20;73(16):1286-91
pubmed: 19841380
Trends Neurosci. 2005 Jul;28(7):348-52
pubmed: 15913799
Neurology. 2012 Mar 13;78(11):781-6
pubmed: 22323743
Fam Cancer. 2003;2(2):101-8
pubmed: 14574159
Cancer Causes Control. 2010 May;21(5):697-707
pubmed: 20054708
Nat Rev Cancer. 2011 Oct 24;11(11):812-23
pubmed: 22020207
Int J Circumpolar Health. 2019 Dec;78(1):1571383
pubmed: 30724720
Neurogenetics. 2009 Apr;10(2):157-9
pubmed: 19020907
Int J Cancer. 2012 Oct 15;131(8):1904-11
pubmed: 22278152
Mov Disord. 2014 May;29(6):750-5
pubmed: 24357540
Arch Neurol. 2012 Dec;69(12):1572-7
pubmed: 22945795
Mov Disord. 2014 Sep;29(10):1325-6
pubmed: 25048644
Neurology. 2007 Oct 9;69(15):1542-50
pubmed: 17699801
Aust N Z J Public Health. 2014 Feb;38(1):35-8
pubmed: 24494943
Mov Disord. 2011 Nov;26(13):2343-6
pubmed: 21954089
Neurology. 2011 Jun 7;76(23):2002-9
pubmed: 21646627
J Neural Transm (Vienna). 2011 Aug;118(8):1199-207
pubmed: 21298300
Ann N Y Acad Sci. 2009 Feb;1155:324-34
pubmed: 19250224
Neurology. 2008 Nov 11;71(20):1650; author reply 1650-1
pubmed: 19001259